Biofrontera AG (LSE:B8F) - Share price - Overview

Stock Report

Biofrontera AG B8F

Last Price
£-

Day Change
-|-%

As of -
- | GBP
Minimum 15 Minutes Delay.

Last Close-
Day Range-
Mkt Cap42.45Mil
52-Wk Range-
Yield %-
ISINDE0006046113
Volume-
P/E-
P/S-
P/CF-

Share Price

Financials
201420152016
More ...
Income Statement
Revenue3.104.146.13
Operating Income-9.53-10.23-11.78
Net Income-10.72-11.20-10.58
Basic EPS-0.43-0.42-0.36
Avg. Diluted Shares Outstanding252730
Balance Sheet
Current Assets11.097.2221.98
Non Current Assets2.922.271.90
Total Assets14.019.5023.88
Current Liabilities3.263.084.44
Total Liabilities14.0314.318.04
Total Equity-0.02-4.8115.84
Cash Flow
Operating Cash Flow-7.93-9.72-10.74
Capital Expenditure-0.16-0.18-0.48
Free Cash Flow-8.09-9.90-11.22

In millions, except "Basic EPS". Currency is EUR.

Company Profile

Biofrontera AG is a biopharmaceutical company. The company is engaged in the development of medical cosmetics and dermatological drugs for the care and treatment of skin diseases.

Sector

Healthcare

Industry

Biotechnology

Stock Style

Small-Growth

Fiscal Year Ends

December

Employees

94
Key Stats
More ...
Price/Earning TTM-
Price/Book-
Price/Sales TTM-
Rev Growth (3 year avg)25.32
EPS Growth (3 year avg)-
Operating Margin % TTM-192.14
Net Margin % TTM-172.57
ROE TTM-191.77
Debt/Equity0.23
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.